NGM — NGM Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $128.53m
- -$15.65m
- $4.42m
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors
U.S. STOCKS ON THE MOVE-Coherus, Moderna
U.S. STOCKS ON THE MOVE-Rivian, Terran Orbital, Longboard Pharmaceuticals
U.S. STOCKS ON THE MOVE-Apple, NGM Biopharmaceuticals, Voyager Therapeutics
NGM Biopharmaceuticals rises on takeover interest from shareholder group
NGM Biopharmaceuticals rises on potential go-private deal
Brief: NGM Biopharmaceuticals Received Non-Binding Expression Of Interest From Column Group
NGM Biopharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: NGM Biopharmaceuticals Q3 Net Income USD -28.797 Million
NGM Biopharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Ngm Bio Announces Oral Plenary Presentation Of Data From Phase 2B Alpine 4 Trial Of Aldafermin
NGM Biopharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: NGM Biopharmaceuticals Q2 Net Income USD -38.3 Million
Brief: Ngm Bio Announces Presentation Of Data From Phase 2 Investigator-Sponsored Trial Of Aldafermin
NGM Biopharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: NGM Biopharmaceuticals Q1 net loss USD 47.6 million